VIEW
IN BROWSER
EDITOR'S
NOTE: Big4Bio newsletters will not be
published from Dec 16, 2025, to Jan 4, 2026; they
will resume distribution on Monday, Jan 5, 2026.
|
 |
| DEcember
12, 2025 |
| Covering
Life Sciences Drugs, Diagnostics, Devices,
Digital Health |
|
|
|
* may need subscription to view |
 |
| Boston's
most flexible contract vivarium
lab space: Start with a few study
cages and grow. |
|
Learn More
→ |
|
|
- BioPorto: Changes to the Executive
Management More
- Centessa Pharmaceuticals: CEO Transition
as Company Advances Strategy to Extend
Orexin Leadership Into Multiple Neuroscience
Indications More
- Innoviva Specialty Therapeutics:
Publication in The Lancet of Positive
Zoliflodacin Phase 3 Data for the Treatment
of Uncomplicated Urogenital Gonorrhea More
More*
- Insilico Medicine and TaiGen: Achieves
License Agreement to Develop and
Commercialize AI-driven PHD Inhibitor for
Anemia of Chronic Kidney Disease (CKD) More
- Marengo: Will Present Initial Results From
Invikafusp Alfa and TRODELVY Combination
Study, STARt-002, at the 2025 San Antonio
Breast Cancer Symposium More
- Pillar Biosciences and AstraZeneca: Expand
Liquid Biopsy Access Partnership to China More
- Relay Therapeutics: Efficacy Subset Analysis
of Zovegalisib (RLY-2608) + Fulvestrant in
Breast Cancer Patients Pre-Treated With SERD
or With ESR1 Mutations at SABCS 2025 More
- Sōlaria Biō: Breakthrough Study
Demonstrating Connection Between Gut Barrier,
Inflammation and Bone Health More
- TransCode Therapeutics and Quantum Leap
Healthcare Collaborative: Launch a Phase 2a Dose-expansion
Trial With TTX-MC138, Following Positive Readouts
From TransCode’s Phase 1 Trial More
|
|
 |
 |
The
Charles River CFO Advantage
Reassessing your business plan?
We provide financial leadership.
Smart. Nimble. Flexible. |
|
Learn More
→ |
|
|
|
- Dyne Therapeutics: Closing of Upsized Public
Offering of Common Stock and Full Exercise by
Underwriters of Option to Purchase Additional
Shares More
- Enveric Biosciences: Exercise of Warrants
for $3.1 Million Gross Proceeds More
- Get Full Access to BYTE51 Life Sciences
Intelligence for 50% Off More
- JPM
Week Conference Readiness Packages (Big4Bio
Subscriber Discount) More
- Kymera Therapeutics: Closing of Upsized $602
Million Public Offering and Full Exercise of
Underwriters’ Option to Purchase Additional
Shares More
- Navigating Post-IPO Financial Reporting More
|
|
 |
Pace®
Life Sciences
The CDMO That Takes You Further.
Your partner for Product
Development, Manufacturing,
Analytical Testing, Regulatory
Consulting & Operational
Support. |
|
Learn More
→ |
|
|
|
- BioPharmGuy News: Pre-Holiday Roast, New Flu
Dropped, Purdue Tumbles, High Energy Decision
More
- More on Rhythm Reporting Imcivree’s Key
Weight Loss Data From Phase 2 Prader-Willi
Trial More*
- Pre-Clinical Trial Giant Eyes
Organ-on-a-Chip Companies After Activist
Investor Pressure More*
- Predicting Trends and Aligning Priorities:
How Point32Health’s New CEO Plans to Break
Even More*
- Sarepta CEO Given First Equity Award in 8
Years More*
- Subscribe to LifeSci Startup for
Updates on US Startups More
- The Big4Bio Podcast: Every Moment
Matters: Integrating AI into Drug Discovery
Podcast
|
|
|
DISCOVER COMPANIES |
|
Big4Bio: Boston Life Science
Company Directory |
|
Locate a specific company or
explore new companies in life
science. |
|
Explore
our Company Directory
|
Provided courtesy
of
 |
|
|
|
Feature your company |
| Apply
to have your company
showcased by Big4Bio |
|
|
|
|
|
 |
|
Premier Executive Search and
Talent Advisory Firm Slone
Partners Launches Fractional
Talent Service to Deliver
On-Demand Leaders and Specialists
|
|
Learn More
→ |
|
|
- M&A in Life Sciences: The Turning
Tide – Why Now is a Strategic Inflection for
Biopharma and Biotech More
- ICYMI: CEO’s Perspective: Big Moves Come
with Big Responsibility More
- ICYMI: CEO’s Perspective: The High Cost of
Job Hopping More
- ICYMI: Elevating Executive Presence: A
Blueprint for Life Sciences and Biotech
Leaders More
- ICYMI: The Power of Peer Learning - Why Even
Top Biotech Leaders Need Mentorship More
- ICYMI: What’s Next in Precision Medicine:
Leadership Challenges and Opportunities More
- The Rise of Fractional Talent in Life
Sciences: What to Expect in 2026 More
|
|
 |
|
|
|
You are
receiving this email because
you signed up for one of our
newsletters at Big4Bio.com,
signed up at one of our
partner or sponsor events,
or given as a gift
subscription by your firm or
organization. Unsubscribe
Big4Bio:Boston,
all rights reserved 2025
© 2025
Big4Bio, a division of
BigBio Communications. All
rights reserved.
|
|
|
|
|
